EWM
BIB icon

Edge Wealth Management’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Edge Wealth Management’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-200
Closed -$11K – 591
2018
Q1 		$11K Hold
200
– – ﹤0.01% 368
2017
Q4 		$11K Buy
+200
New +$11.3K ﹤0.01% 363
2017
Q1 		– Sell
-500
Closed -$20K – 523
2016
Q4 		$20K Hold
500
– – 0.01% 274
2016
Q3 		$24K Buy
+500
New +$23.8K 0.01% 252

Other funds holding BIB

OPPM
Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BA
BKS Advisors Southfield, Michigan $249M AUM 14.37% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
BRC
Bell Rock Capital Rehoboth Beach, Delaware $81M AUM 9.85% 1-Year Est. Return

Edge Wealth Management's BIB Position: Q2 2018 in Review

Edge Wealth Management sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q2 2018, closing a stake of 200 shares — an estimated $11K sold.

Edge Wealth Management first reported a position in BIB in Q3 2016 and held it in 4 quarters. The position peaked at $24K in Q3 2016. 38 funds tracked by Wall St. Rank hold BIB as of Q2 2018.

  • Edge Wealth Management reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q2 2018 after selling out during the quarter.
  • Edge Wealth Management sold 200 ProShares Ultra NASDAQ Biotechnology shares in Q2 2018, an estimated $11K.
  • Edge Wealth Management first reported a position in ProShares Ultra NASDAQ Biotechnology in Q3 2016 and held it in 4 quarters.
  • Edge Wealth Management's ProShares Ultra NASDAQ Biotechnology position peaked at $24K in Q3 2016.
  • 38 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q2 2018.

Based on Edge Wealth Management's 13F filing for Q2 2018, filed 17 Jul 2018.